Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

882 results about "Interferon" patented technology

Interferons (IFNs) are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.

Nanobody Targeting Human Serum Albumin and Its Application

The present invention discloses a human serum albumin-targeting nanobody and its application. A variety of human serum albumin-targeting nanobodies that can be used to construct long-acting fusion protein drugs and their immune screening methods are disclosed. The antibody is composed only of the heavy chain variable region and can be fused and expressed with therapeutic proteins or polypeptide drugs such as interleukin, interferon, and tumor necrosis factor in an Escherichia coli expression system. The fusion protein has the activity of specifically binding to human serum albumin, has a relatively high affinity, can effectively extend the drug half-life, and does not affect the biological activity of the recombinant protein drug at the same time.
Owner:CHANGCHUN INST OF BIOLOGICAL PRODS

Compounds and compositions for treating conditions associated with sting activity

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and / or hydrate, and / or cocrystal, and / or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
Owner:IFM DUE INC

Culture medium and culture method for persistent DC-CIK cells and application of culture medium and culture method

The invention relates to a culture medium and a culture method of persistent DC-CIK cells and application of the culture medium and the culture method, and belongs to the technical field of cell culture. The invention provides a culture medium for persistent DC-CIK cells, which takes a serum-free culture medium as a solvent and comprises a recombinant human granulocyte macrophage colony stimulating factor, a recombinant human interleukin-12, a recombinant human tumor necrosis factor-alpha, a recombinant human interferon-gamma, L-cysteine, glutathione, ginseng polysaccharide and streptomycin sulfate. According to the culture medium and the culture method of the persistent DC-CIK cells, proliferation and growth of the DC-CIK cells can be promoted, and very high tumor killing activity of the DC-CIK cells can be maintained for a long time.
Owner:广东壹加再生医学研究院有限公司

Grass carp gamma interferon fusion protein as well as mutant, coding gene and application thereof

The invention discloses a grass carp gamma interferon fusion protein as well as a mutant, a coding gene and application thereof. In order to improve the expression quantity or expression efficiency of the grass carp gamma interferon, codon optimization and mutation are carried out on the coding gene of the grass carp gamma interferon to obtain the grass carp gamma interferon mutant. The fusion protein is further obtained by connecting the grass carp gamma interferon mutant with the C end of the grass carp ferritin heavy chain subunit of which the last 17 amino acids are removed through a connecting peptide. In order to further improve the antiviral activity of the fusion protein, the obtained fusion protein is subjected to single-point mutation, and the titer of the fusion protein is remarkably improved. The fusion protein is expressed by a silkworm cell eukaryotic expression system, and the fusion protein shows a conformation suitable for the interferon to play functions based on the ferritin self-assembly characteristic, so that the titer of the interferon in a host is effectively improved, and the in-vivo and in-vitro half-life period of the interferon is prolonged. The invention has application prospects in preparation of drugs or reagents for preventing or treating viral diseases of grass carp and the like.
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI

Application of GATA3 inhibitor and PD1 inhibitor in preparation of medicine for treating breast cancer

The invention relates to application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicine. The invention discloses application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer. The GATA3 regulates the transcription regulation of IFNbeta by inhibiting the enhancer activity of IFNB1, down-regulates an I-type interferon signal channel, inhibits the secretion of an MHC-I antigen presentation channel and a chemotactic factor CCL5 of breast cancer cells, reduces immune recognition, and achieves the purpose of immune escape. The immunotherapy for inhibiting GATA3 combined with the PD1 inhibitor to treat breast cancer effectively treats breast cancer mice, improves the IFN beta level in the mice, promotes the MHC-I antigen presentation pathway of the mice, improves the CCL5 level in the mice, and improves the CD8 + T cell level in a tumor immune microenvironment, thereby reducing tumor occurrence and inhibiting tumor growth.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN

Immunosensor for detecting cytokine interferon gamma through electrochemiluminescence as well as preparation method and application of immunosensor

The invention discloses an immunosensor for detecting cytokine interferon gamma through electrochemiluminescence as well as a preparation method and application of the immunosensor. The immunosensor comprises a three-electrode system consisting of an immunoelectrode, a reference electrode and a counter electrode, the immunoelectrode is a VMSF modified electrode confined to cerium dioxide nano enzyme and platinum nano particles, and is obtained by covalently immobilizing an IFN-gamma antibody and closing a non-specific site; when the immunosensor is used for detection, a solution containing luminol is used as an electrolyte. The CeO2 and the PtNPs which are confined in the nano channel show a remarkable synergistic catalysis effect. Compared with direct modification on a plate electrode, CeO2-PtNPs has higher catalytic activity and stability. The sensor provided by the invention is used for INF-gamma detection, has the advantages of high sensitivity, low detection limit and wide detection range, does not need complex pretreatment and separation processes during detection, reduces the detection cost, is simple to operate, and is suitable for large-scale application.
Owner:HANGZHOU FIRST PEOPLES HOSPITAL

Benzothiophene compound as well as pharmaceutical composition, pharmaceutical preparation and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a benzothiophene compound as well as a pharmaceutical composition, a pharmaceutical preparation and application thereof. The benzothiophene compound has a structure as shown in a formula (I), has a very strong excitation effect on an STING-mediated interferon signal channel, can be used as a small-molecule STING agonist, and is used for clinical treatment (especially immunotherapy) of tumors or infectious diseases. # imgabs0 #
Owner:BEIJING WINSUNNY PHARMA CO LTD +1

Novel coronavirus SARS-CoV-2 mutant vaccine and application

The invention relates to a novel coronavirus SARS-CoV-2 mutant vaccine and application, the vaccine comprises a fusion protein, and the fusion protein comprises: (1) interferon or a functional fragment thereof; (2) a novel coronavirus SARS-CoV-2Omicron mutant strain S protein or a functional fragment of the novel coronavirus SARS-CoV-2Omicron mutant strain S protein; and (3) an immunoglobulin Fc region. Molecule and process optimization of the fusion protein comprises improvement of process developability and immunogenicity, and the vaccine can improve immunogenicity and antibody titer of a mutant new crown antigen through convergence mutation design, efficiently generate a neutralizing antibody, significantly improve defense ability to a variant strain, and can be massively and industrially produced.
Owner:LIVZON MABPHARM

Cyclic peptide inhibitor aiming at human STING (stimulating interferon gene) and application thereof

The invention relates to a cyclopeptide inhibitor aiming at human STING (stimulating interferon gene) and application of the cyclopeptide inhibitor. The cyclic peptide can specifically bind to and inhibit activation of human STING. The invention also provides a nanoparticle delivery system for loading the cyclopeptide on a cationic polymer PBAE and an amphiphilic polymer pDMA-pEPEMA, and a preparation method of the nanoparticle delivery system. The cyclic peptide and the nanoparticles thereof can be used for preparing medicines for treating autoimmune diseases (such as systemic lupus erythematosus and the like) caused by excessive activation of the cGAS-STING signal pathway. Compared with the existing small molecule STING inhibitor, the cyclopeptide inhibitor provided by the invention has higher specificity, stability and inhibition effect.
Owner:SHANDONG UNIV +1

New application of emodin as ribonuclease inhibitor

InactiveCN119139281Aclearly targetedOrganic active ingredientsAntiviralsEndoribonucleaseRNA - Ribonucleic acid
The invention discloses a novel application of emodin as an endonuclease inhibitor. The emodin inhibits replication and transmission of viruses by inhibiting the activity of NSP15 ribonuclease, and recovers host interferon reaction so as to enhance the antiviral effect. The application has the advantages that the action target of the emodin is defined, the effectiveness of the emodin in the aspect of preventing and treating coronavirus infection is further revealed, and the broad-spectrum antiviral potential of the emodin is embodied through the link of playing the antiviral effect by inhibiting the virus replication link; the researches provide candidate drugs and scientific basis for research and development of novel broad-spectrum anti-coronavirus drugs, and promote clinical application of the anti-virus traditional Chinese medicines.
Owner:INST OF BASIC THEORY OF TCM CHINA ACADEMY OF CHINESE MEDICAL SCI

Effect of Intestinia butyriproducens bacteria in anti-tumor immunotherapy

The invention discloses an effect of an Intestinia butyriproducens bacterium in anti-tumor immunotherapy, and finds that colonization of the Intestinia butyriproducens bacterium in intestinal tracts can inhibit growth of CT26 mouse subcutaneous transplanted tumors with poor response to the tumor immunotherapy, meanwhile, growth of human colorectal cancer cells is remarkably inhibited, and apoptosis of tumor cells is promoted for the first time. The application of the Intestinia butyriproducens bacterium in the anti-tumor immunotherapy has the advantages that the effect of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy is achieved, and the application of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy is achieved. Meanwhile, after colonization of the strain and combined administration of PD-1 monoclonal antibodies, the proportion of CD8 + T cells in mouse tumor infiltration lymphocytes is increased, the proportion of depleted PD-1 + CD8 + T cells is reduced, and the proportion of CD8 + T cells releasing functional cell factors interferon gamma and granzyme B is also increased, which shows that after colonization of the strain, the curative effect of tumor immunotherapy can be enhanced, and the tumor immunotherapy effect can be enhanced. The immunoregulation capability and the great clinical application value are realized.
Owner:CHINA PHARM UNIV

An enhanced tumor vaccine adjuvant

The present invention discloses an enhanced tumor vaccine adjuvant, and specifically relates to the field of vaccine adjuvants, the adjuvant comprising granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-9 (IL-9), gamma interferon (IFN-γ) and at least one additional immunomodulatory factor, wherein the immunomodulatory factor is selected from tumor-specific antigen WT1, CD40 ligand (CD40L), Toll-like receptor agonist or a combination thereof. The tumor vaccine adjuvant of the present invention can enhance the body's immune response to the tumor vaccine and improve the prevention and treatment effect of the tumor vaccine on tumors.
Owner:KELANCE BIOPHARMACEUTICAL (SHANGHAI) CO LTD

Use of HPK1 inhibitor in treatment of interferon-related diseases

Disclosed in the present invention is a class of completely-new HPK1 inhibitory active compounds. In the present invention, the intrinsic mechanistic link of HPK1 kinase to viral infection is explained for the first time. The compounds of the present invention are useful in the treatment of interferon-related diseases, particularly viral infections. Further, provided in the present invention is a method for treating interferon-related diseases using the compounds of the present invention.
Owner:ASCLEPIEION PHARM CO LTD

Method for treating interferonopathies

Methods for interfering or controlling IFN induction, IFN production and / or IFN activity are disclosed, harnessing viral mechanisms for evading or suppressing host anti-viral immune reactions. These methods comprise administration of one or more viral messenger RNAs (mRNAs) coding for proteins or peptides that control or interfere with signal transduction upstream and / or downstream of IFN induction, thereby providing a means for preventing or treating diseases, disorders or conditions associated with increased IFN production, such as cancer, autoimmune diseases, inflammatory diseases and interferonopathies.
Owner:IMMUNOBEL THERAPEUTICS LTD

Recombinant expression cat interferon-omega gene as well as preparation method and application thereof

PendingCN121320359AViral antigen ingredientsAntiviralsDual promoterTGE VACCINE
The invention relates to a recombinant expression cat interferon-omega gene and a preparation method and application thereof, the nucleotide sequence of the cat interferon-omega gene is as shown in SEQ ID NO.1, and the cat interferon-omega gene is obtained by introducing an Fc fusion fragment to the C terminal and / or N terminal of the natural gene sequence of the cat interferon-omega. XTEN or PAS is introduced to prolong a peptide fragment, and original glycosylation modification sites on a natural sequence are reserved. The method comprises the following steps: cloning a cat interferon-omega gene into an expression vector containing double promoters, further transfecting into a cell, carrying out stable cloning and screening, establishing a high-expression cell strain, and carrying out fermentation culture in a bioreactor. According to the invention, the cat interferon-omega gene is subjected to multiple modification and is efficiently expressed in a CHO-K1GS system, so that the protein yield, the stability and the half-life period are remarkably improved; the obtained fusion protein is high in purity and strong in activity, can obviously enhance immune response and protection effect when being matched with cat vaccines, and is good in safety.
Owner:HAODONG BIOPHARMACEUTICALS (HANGZHOU) CO LTD

CD80 extracellular domain polypeptides and their use in cancer treatment

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and / or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and / or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
Owner:FIVE PRIME THERAPEUTICS INC

Nanoparticles for targeted protein degradation and degradation method

The invention discloses a nanoparticle for targeted protein degradation and a degradation method. The nanoparticles can enhance uptake of cells and effectively encapsulate specific antibodies for recognizing target proteins, and meanwhile, the interferon component can induce expression of TRIM family proteins in the cells. After ingestion into the cell, the antibody released by the nanoparticle can bind to the target protein and bind to the TRIM family protein to mediate degradation of the target protein. In this process, although the TRIM family protein is continuously consumed, the TRIM family protein can be compensated by the TRIM family protein expression induced by the particle of the invention, thereby maintaining efficient degradation.
Owner:PEKING UNIV

Surrogate interferon agonists

The present disclosure relates to compositions and methods relating to interferon agonists and their engineered polypeptides. The engineered polypeptides have specificity to receptors in immune systems mediated by Type I interferon (IFN). The present disclosure also relates to methods and system for identifying surrogate agonists for cell surface receptors including dimeric and trimeric receptors.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Multivalent interferon particles compositions and methods of use

Disclosed herein are multivalent particles that comprise multiple copies of an interferon (IFN) fusion proteins, wherein fusion protein comprises interferon polypeptide fused to a transmembrane domain and expressed on the surface of the multivalent particle. It also discloses composition and uses of the multivalent particles for treating diseases, disorders, and infections.
Owner:ACHELOIS BIOPHARMA INC

Application of fructose-1, 6-diphosphate in preparation of medicine for preventing and treating herpes simplex virus type 1 infection

The invention belongs to the field of medicines, and particularly relates to application of fructose-1, 6-diphosphate in preparation of a medicine for preventing and treating herpes simplex virus type 1 infection. The fructose-1, 6-diphosphate (FBP) can be used for inhibiting replication of RNA (Ribonucleic Acid) and DNA (Deoxyribose Nucleic Acid) viruses in vitro and in vivo. Experiments show that the inhibition effect does not depend on I-type interferon-mediated innate immunity to a great extent, but occurs through HMGB1 (High Mobility Group Box 1). After virus infection, FBP reduces the protein level of HMGB1 by promoting lysosome degradation of HMGB1. In addition, the FBP can directly inhibit the combination of the HMGB1 and the viral genome, so that the virus replication is inhibited. The key effect of FBP in inhibition of virus replication is highlighted through research, and a potential target spot for controlling virus infection is provided.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Two-dimensional risedronate manganese nanobelt as well as preparation method and application thereof

The invention provides a preparation method of a two-dimensional nanobelt. The two-dimensional manganese risedronate nanobelt (RMn-NBs) is prepared from Mn < 2 + > and risedronate sodium by using a coordination self-assembly technology. The raw materials are cheap and easy to obtain, and the preparation process is simple, easy to operate and good in controllability. The two-dimensional risedronate manganese nanobelt can inhibit a hypoxia-inducible factor / vascular endothelial growth factor (HIF-1alpha / VEGF) through risedronate sodium so as to enhance the radiotherapy effect; meanwhile, Fenton-like reaction of Mn < 2 + > is utilized to amplify oxidative stress mediated by radiotherapy, a GMP-AMP synthetase stimulating factor (cGAS-STING) pathway of an interferon gene ring is synchronously activated, secretion of I-type interferon is promoted, ICD (immunogen cell death) is effectively induced, and the immunogen cell death rate is increased. And the effects of CD8 + T cell dependent systemic anti-tumor immunity and checkpoint blocking immunotherapy on primary and metastatic tumors are greatly enhanced. The RMn-NBs is used as a novel nanoscale in-situ radiotherapy vaccine, and has good biocompatibility and treatment effect.
Owner:NANJING UNIV OF POSTS & TELECOMM

Targeted human serum albumin nano antibody and application thereof

The invention discloses a targeted human serum albumin nano antibody and application thereof. The invention discloses a plurality of targeted human serum albumin nano antibodies capable of being used for constructing long-acting fusion protein drugs and an immune screening method thereof. The antibody is only composed of a heavy chain variable region and can be subjected to fusion expression with interleukin, interferon, tumor necrosis factors and other therapeutic proteins or polypeptide drugs in an escherichia coli expression system, the fusion protein has the activity of specific binding with human serum albumin, the affinity is high, the half-life period of the drugs can be effectively prolonged, and the anti-tumor effect is good. Meanwhile, the biological activity of the recombinant protein medicine is not influenced.
Owner:CHANGCHUN INST OF BIOLOGICAL PRODS

Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof

Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
Owner:NAMMI THERAPEUTICS INC

Grass carp IFNf interferon and truncated protein, and application thereof in antiviral or antibacterial treatment

The invention relates to the field of biological medicine and aquatic products, and discloses a grass carp IFNf interferon and truncated protein and application thereof in virus resistance or bacterium resistance. The applicant discovers the new subtype IFNf of the grass carp interferon for the first time, the protein coded by the new gene has an efficient antiviral effect, and the derived peptide AMP-G2 of the grass carp interferon has broad-spectrum antibacterial activity. The sensitivity of the grass carp interferon IFNf to grass carp reovirus (GCRV) infection is higher than that of other interferon, and the grass carp interferon IFNf shows obvious antiviral activity on the cellular level and can be used for preparing antiviral drugs. The interferon-derived peptide provided by the invention is a host natural peptide, is small in molecular weight and simple to synthesize, has a remarkable bactericidal effect on various bacteria and fungi, and can be used for preparing broad-spectrum antibacterial agents or antibacterial drugs.
Owner:INST OF AQUATIC LIFE ACAD SINICA